Phathom's Voquezna: A Breakthrough Drug Facing Marketing Challenges [Seeking Alpha]
Phathom Pharmaceuticals, Inc. (PHAT)
Last phathom pharmaceuticals, inc. earnings: 3/19 08:31 am
Check Earnings Report
Company Research
Source: Seeking Alpha
Follow Play 9min Summary Phathom Pharmaceuticals developed Voquezna, a first-in-class PCAB, licensed from Takeda, for acid-related disorders. Voquezna's FDA approval for erosive esophagitis is based on superior efficacy over PPIs, particularly in severe cases. Voquezna prescriptions have rapidly increased, though competition and marketing costs present key risks to Phathom's growth. Phathom's financials show a cash runway until 2026, with significant cash burn but strong potential market opportunity. Despite its promise, I recommend holding Phathom stock due to uncertainties in marketing execution and upcoming competition. Tharakorn/iStock via Getty Images Introduction Phathom Pharmaceuticals NASDAQ: PHAT ) markets Voquezna (vonoprazan), a novel, first-in-class small-molecule potassium-competitive acid blocker (PCAB), to treat H. pylori infection, erosive esophagitis, and non-erosive GERD. Takeda has approved vonoprazan for acid-related disorders under the brand
Show less
Read more
Impact Snapshot
Event Time:
PHAT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PHAT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PHAT alerts
High impacting Phathom Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
PHAT
News
- Amoxicillin Market Research Report 2024: Combination Therapies and Immunotherapy Trends Shaping Future Landscape - Global Long-term Forecast to 2028 and 2033 [Yahoo! Finance]Yahoo! Finance
- SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT)PR Newswire
- Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $26.00 price target on the stock.MarketBeat
- Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $26.00 price target on the stock.MarketBeat
- Following Up On Phathom Pharmaceuticals [Seeking Alpha]Seeking Alpha
PHAT
Earnings
- 8/8/24 - Beat
PHAT
Sec Filings
- 8/22/24 - Form SC
- 8/19/24 - Form 8-K
- 8/19/24 - Form 424B5
- PHAT's page on the SEC website